Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim (BI) for G-Protein Coupled Receptors (GPCRs)
Shots:
- Domain to receive upfront- milestones- and royalties on sales from Boehringer Ingelheim
- The focus of the agreement is to discover & develop GPCRs- using Domain’s DTect-All and bioSens-All technology to characterize compounds for Neuropsychiatric Diseases
- GPCRs are receptors present in CNS- activates by binding with stimulus or ligand and regulates the functions of brain
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
